Search results for "bromi"

showing 10 items of 777 documents

Cytochrome P450-dependent metabolism of caffeine in [i]Drosophila melanogaster[/i]

2014

Caffeine (1, 3, 7-trimethylxanthine), an alkaloid produced by plants, has antioxidant and insecticide properties that can affect metabolism and cognition. In vertebrates, the metabolites derived from caffeine have been identified, and their functions have been characterized. However, the metabolites of caffeine in insects remain unknown. Thus, using radiolabelled caffeine, we have identified some of the primary caffeine metabolites produced in the body of Drosophila melanogaster males, including theobromine, paraxanthine and theophylline. In contrast to mammals, theobromine was the predominant metabolite (paraxanthine in humans; theophylline in monkeys; 1, 3, 7-trimethyluric acid in rodents…

MaleMetabolite[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionlcsh:MedicineéthanolPharmacology[ SDV.BA ] Life Sciences [q-bio]/Animal biologychemistry.chemical_compound0302 clinical medicineCytochrome P-450 Enzyme Systemmétabolitelcsh:SciencemetabolitesParaxanthinecaféinecaffeineAnimal biology0303 health sciencesMultidisciplinarybiologyAlkaloid[SDV.BA]Life Sciences [q-bio]/Animal biologymétabolisme des xénobiotiquesxenobiotic metabolism3. Good healthBiochemistryAlimentation et Nutritioncaffeine;xenobiotic metabolism;drug metabolism;metabolites;drosophila melanogaster;theobromine;ethanolCaffeinemedicine.drugResearch Articledrosophila melanogasterXenobioticsmétabolisme enzymatique03 medical and health sciencesBiologie animalemedicineAnimalsFood and NutritionTheophyllineGene SilencingTheobromine030304 developmental biologytheobrominelcsh:RfungiCytochrome P450drug metabolismchemistrybiology.proteinlcsh:Qethanol[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryDrug metabolism
researchProduct

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B

2015

SummaryIntroductionAccording to current GOLD strategy, patients with COPD classified as groups A and B may be treated with inhaled bronchodilators, either long-acting β2-agonist (LABA) or long-acting muscarinic antagonist (LAMA). However, there is little guidance on which class of agent is preferred and a lack of prospective data to differentiate the two.MethodsIn this study, we performed post-hoc analyses of pooled data from two prospective, controlled clinical trials comparing the LABA indacaterol and LAMA tiotropium in 1422 patients with moderate airflow limitation and no history of exacerbations in the previous year. This population fits the definitions of GOLD A and B groups and could …

MalePulmonary and Respiratory MedicineEfficacyPopulationINDEXESQuinolonesOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease Chronic ObstructiveHumansMedicineCOPDCOHORTProspective StudiesGOLDTiotropium BromideeducationDYSPNEAIndacateroleducation.field_of_studyCOPDDose-Response Relationship Drugbiologybusiness.industryTiotropiumONCE-DAILY INDACATEROLMuscarinic antagonistForced Expiratory Flow RatesBaseline Dyspnea IndexMiddle AgedLamabiology.organism_classificationmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesClinical trialTreatment OutcomeAnesthesiaIndansCohortIndacaterolFemalebusinessCLINICAL METHODSFollow-Up Studiesmedicine.drugRespiratory Medicine
researchProduct

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with mod…

2015

Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. Methods This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to <80% predicted) to QVA149 110/50 µg o.d. or TIO 18 µg o…

MalePulmonary and Respiratory MedicineVital capacitymedicine.drug_classChronic Obstructive Pulmonary DiseaseVital CapacityScopolamine DerivativesQuinolonesCOPD PharmacologyDrug Administration SchedulePulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodQuality of lifeForced Expiratory VolumeFormoterol FumarateBronchodilatorHumansMedicine1506Tiotropium BromideAdrenergic beta-2 Receptor AgonistsAgedCOPDbusiness.industryMiddle Agedmedicine.diseaseGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeEthanolaminesBronchodilator AgentsAnesthesiaIndansQuality of LifeIndacaterolFemaleFormoterolbusinessmedicine.drugThorax
researchProduct

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in…

2014

BACKGROUND: To further assess the safety profile of the fixed-dose combination of indacaterol and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of individual patient-level factors and time by integrating the patient-level safety data from the QVA149 clinical programme with relevant information from the independent indacaterol and glycopyrronium safety databases.METHODS: Data from 11,404 patients with chronic obstructive pulmonary disease (COPD) were pooled from 14 clinical studies of QVA149, indacaterol and glycopyrronium of ≥3 month's duration with at least two of the treatment groups: QVA149 110/50 μg, glycopyrronium 50 μg, indacaterol 150 μg, placebo or tiotr…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationScopolamine DerivativesQuinolonesPlaceboPooled analysisPulmonary Disease Chronic ObstructiveRisk FactorsInternal medicinemedicineHumansTiotropium BromideIndacaterolAgedCOPDbusiness.industryTiotropiumHazard ratioQVA149Middle Agedmedicine.diseaseGlycopyrrolateConfidence intervalBronchodilator AgentsDrug CombinationsTreatment OutcomeAnesthesiaIndansIndacaterolDrug Therapy CombinationFemaleGlycopyrroniumSafetybusinessBody mass indexMacemedicine.drugRespiratory Medicine
researchProduct

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease

2016

Abstract Background Long-term safety, particularly cardiovascular safety, is of special interest in maintenance treatment of chronic obstructive pulmonary disease (COPD) with long-acting β 2 -agonists and long-acting muscarinic antagonists, given potential cardiovascular effects. Methods Two 52-week Phase III trials (TONADO ® ) investigated tiotropium/olodaterol (5/5 and 2.5/5 μg) versus tiotropium 2.5, 5 μg and olodaterol 5 μg. In a pre-specified safety analysis, investigator-reported treatment-emergent adverse events (AEs), electrocardiogram and laboratory data were pooled. All serious AE (SAE) reports were reviewed by an independent Adjudication Committee, which assessed whether deaths, …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyMedDRAComorbidityMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodForced Expiratory VolumeInternal medicineAdministration InhalationmedicineHumans030212 general & internal medicineTiotropium BromideAdverse effectAdrenergic beta-2 Receptor AgonistsAgedCOPDbusiness.industryIncidenceIncidence (epidemiology)OlodaterolTiotropium bromideMiddle Agedmedicine.diseaseComorbidityBenzoxazinesBronchodilator AgentsDrug Combinations030228 respiratory systemchemistryCardiovascular DiseasesAnesthesiaFemalebusinessMaceFollow-Up Studiesmedicine.drug
researchProduct

Biphenyl and fluorinated derivatives: liver enzyme-mediated mutagenicity detected in Salmonella typhimurium and Chinese hamster V79 cells.

1992

Abstract Hepatocarcinogenic polychlorinated and polybrominated biphenyls usually show negative results in in vitro mutagenicity assays. Problems in their testing result from their low water solubility and their slow rate of metabolism. We therefore investigated better soluble model compounds, namely biphenyl and its 3 possible monofiuorinated derivatives. In the direct test, these compounds proved tobe nonmutagenic in Salmonella typhimurium TA98 and TA100 (reversion to histidine prototrophy) and in Chinese hamster V79 cells (acquisition of resistance to 6-thioguanine). However, when the exposure was carried out in the presence of NADPH-fortified postmitochondrial fraction of liver homogenat…

MaleSalmonella typhimuriumendocrine systemChinese hamsterAmes testCell LineToxicologychemistry.chemical_compoundStructure-Activity RelationshipCricetulusCricetinaeAnimalsBiotransformationBiphenylbiologyChemistryMutagenicity TestsBiphenyl CompoundsRats Inbred StrainsGeneral MedicineMetabolismbiology.organism_classificationEnterobacteriaceaeIn vitroRatsBiochemistryMicrosomal epoxide hydrolaseMicrosomes LiverPolybrominated BiphenylsMutation research
researchProduct

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

2017

Background and purpose While the efficacy and safety of combined tiotropium and olodaterol in patients with COPD was established in a large clinical trial program, it is important to assess whether clinical data can be applied to geographic patient groups, particularly for East Asian patients who may have a different phenotypic profile to the global trial population. This study aimed to compare the lung function and safety profiles of tiotropium/olodaterol and monocomponents in East Asian and global populations from the TONADO® trials. Materials and methods In the replicate, double-blind, parallel-group, active-controlled, randomized, 52-week, Phase III TONADO studies, patients received tio…

MaleTime FactorsHealth StatusVital CapacityCholinergic AntagonistsPulmonary function testingPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineForced Expiratory Volume030212 general & internal medicineLungLung functionOriginal ResearchCOPDeducation.field_of_studypulmonary functionOlodaterolArea under the curveGeneral MedicineMiddle AgedhumanitiesBronchodilator AgentsDrug CombinationsTreatment OutcomeArea Under CurveFemaleChinamedicine.medical_specialtyPopulationInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health sciencesAsian PeopleDouble-Blind MethodInternal medicinemedicineHumansCOPDTiotropium BromideAdverse effecteducationAdrenergic beta-2 Receptor AgonistsAgedbusiness.industryRecovery of Functionmedicine.diseaseBenzoxazinesrespiratory tract diseasesClinical trial030228 respiratory systemchemistryQuality of Lifeadverse effectsTONADO®businesshuman activitiesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Effects of alkylxanthines on contractility of diaphragm fibres isolated from normal and sensitized guinea-pigs.

1993

Abstract This study investigates the effects of alkylxanthines on twitch tension generated by electrical stimulation (supramaximal pulses, 0·2 ms duration, 1 Hz) of diaphragm muscle fibres isolated from normal and actively-sensitized guinea-pigs. Caffeine, theophylline and theobromine increased, in a concentration-dependent manner (50–500 μm), twitch tension in normal and sensitized diaphragm. Caffeine (500 μm) enhanced contractility to a greater extent than theophylline or theobromine. Twitch potentiation by caffeine (500 μm) was significantly greater in sensitized diaphragm. Verapamil (0·1–100 μm) did not alter twitch contractions in the absence or presence of alkylxanthines in normal or …

Malemedicine.medical_specialtyAdenosineDiaphragmGuinea PigsPharmaceutical ScienceIn Vitro TechniquesDantroleneDantroleneContractilitychemistry.chemical_compoundTheophyllineInternal medicineCaffeinemedicineAnimalsTheophyllineRespiratory systemRats WistarPharmacologyMuscle SmoothSerum Albumin Bovinemusculoskeletal systemElectric StimulationDiaphragm (structural system)Bronchodilator AgentsCulture MediaRatsEndocrinologychemistryVerapamilXanthinesEnprofyllineTheobromineCalciumFemaleImmunizationmedicine.symptomCaffeineExtracellular Spacemedicine.drugMuscle contractionMuscle ContractionThe Journal of pharmacy and pharmacology
researchProduct

Apparent vs real effects of scopolamine on the learning of an active avoidance task.

1996

The effects of scopolamine hydrobromide (0.5 and 2 mg/ kg) administered intraperitoneally to Balb/c male mice before or after training in active avoidance were explored in four training sessions and in a subsequent test session, free of drug. Animals given scopolamine prior to training performed better than controls, an effect that was reversed in the session free of drug. However, a deeper analysis of the data permits us to interpret this increment in the number of avoidance responses as a consequence of the increase in activity produced by the drug and not as learning. In the animals injected with scopolamine after sessions no effects were observed. In conclusion, the results of the prese…

Malemedicine.medical_specialtyCognitive NeuroscienceScopolamineMale miceExperimental and Cognitive PsychologyAudiologyTask (project management)Developmental psychologyBehavioral NeuroscienceMicePharmacokineticsMuscarinic acetylcholine receptorTask Performance and AnalysisScopolaminemedicineAvoidance LearningAnimalsMice Inbred BALB CDose-Response Relationship DrugAntagonistBiological activityPsychologyNeuroscienceScopolamine Hydrobromidemedicine.drugNeurobiology of learning and memory
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct